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Background: One of the main features of Alzheimer’s disease (AD) is the presence of Aβ deposits, which
accumulate in the brain years before the onset of symptoms. We and others have demonstrated that cerebral
Aβ-amyloidosis can be induced in vivo by administration of AD-brain extracts into transgenic mice. However, it is
currently unknown whether amyloid formation can be induced using extracts from individuals harboring Aβ
deposits, but not clinical disease.
Results: In this study we analyzed the amyloid-inducing capability of samples from individuals affected by mild
cognitive impairment (MCI) and Non-Demented persons with Alzheimer’s disease Neuropathology (NDAN). Our
results show that inoculation of transgenic mice with MCI and NDAN brain samples accelerated Aβ pathology in a
similar way as extracts from confirmed AD.
Conclusions: This data demonstrate that the sole presence of Aβ aggregates in a given sample, regardless of the
clinical condition, is capable to accelerate Aβ deposition in vivo. These findings indicate that the amyloid-inducing
activity may be present in the brain of people during pre-symptomatic or a-symptomatic stages of AD.Background
Alzheimer’s disease (AD) is a prevalent brain disorder,
mostly affecting individuals over 65 years old [1,2]. Clini-
cally, this progressive and irreversible neurodegenerative
illness is characterized by cognitive decline, which in-
variably leads to dementia [2]. The hallmark neuro-
pathological lesions of AD brain are the extracellular
deposition of misfolded amyloid-β (Aβ) as amyloid
plaques and the formation of neurofibrillary tangles
composed by intracellular aggregates of hyper-phos-
phorylated tau [3]. Aβ aggregates in AD can be found
in a variety of arrangements such as soluble Aβ oligo-
mers, diffuse deposits, dense core senile plaques, vas-
cular deposits, and intra-cellular aggregates, among
others [3,4]. To different degree, all these structures
have been associated to cell toxicity and tissue dys-
function [5-9].* Correspondence: Claudio.Soto@uth.tmc.edu
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article, unless otherwise stated.Accumulation of Aβ aggregates in the brain is thought
to begin many years or even decades before the onset
of AD clinical symptoms [10-13]. Indeed, abundant
amounts of Aβ deposits are detected in the brain of
some subjects affected by mild cognitive impairment
(MCI) [14,15], which is considered a precursor stage of
AD [16,17]. Most patients with amnestic MCI do not
meet the full neuropathologic criteria for AD, but their
pathological features suggest a transitional state evolving
towards AD [14,18]. MCI is a clinical condition usually
defined by subtle memory changes that do not signifi-
cantly affect daily life [19]. MCI does not meet diagnos-
tic criteria for dementia; however, people affected by this
condition are at high risk to convert into AD [16,19,20].
Alternatively, it is widely known that elderly people
usually exhibit cerebral Aβ pathology, even without any
signs of dementia [11,12,21]. In fact, it is not uncommon
to find cases of aged non-demented subjects harboring
abundant amyloid lesions in their brains (here referred
as Non-Demented individuals with Alzheimer’s disease
Neuropathology or NDAN). These cases suggest that
certain arrangements of misfolded Aβ are not associatedentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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with accumulation of misfolded aggregates [11,21].
Recent studies have demonstrated that inoculation of
AD brain homogenates is able to accelerate amyloid de-
position in AD-transgenic mice [22,23]. Furthermore,
AD samples are also able to induce de novo Aβ pa-
thology in animal models that do not spontaneously de-
velop this type of lesions during their whole lifespan
[24,25]. These findings suggest that the accumulation of
Aβ deposits follows a seeding-dependent process of
misfolding and aggregation that can be induced in a
prion-like manner by administration of preformed aggre-
gates [26-30]. Experimental induction of amyloid path-
ology has been achieved by injection of brain samples
from AD patients [22-25] and aged AD-transgenic mice
[23,31,32]. However, there are no reported studies inves-
tigating whether the pathological induction can also be
observed upon inoculation of brain samples from per-
sons at potentially pre-symptomatic or a-symptomatic
stages of AD, which contain substantial cerebral amyloid
deposits, but not overt dementia. In the present study,
we evaluated the Aβ seeding capability of MCI and
NDAN brains in AD-transgenic animals. Strikingly, we
found that MCI and NDAN samples can exacerbate




AD (79 years old, female, AD clinical diagnosis that was
confirmed post-mortem), NDAN (81 years old, male,
non-demented diagnosis) and aged control (59 years old,
male, non-demented diagnosis) brain samples were ob-
tained from the National Disease Research Interchange
(Philadelphia, PA, USA). MCI (95 years old, male, MCI
diagnosis by neuropsychological test) sample was kindly
provided by Dr. Eliezer Masliah (University of California
at San Diego, California, USA). All areas analyzed cor-
responded to the cingulate cortex. Research on hu-
man samples was performed following The Code of
Ethics of the World Medical Association (Declaration
of Helsinki). Informed consent was obtained for expe-
rimentation with human subjects. Samples were manipu-
lated following the universal precautions for working with
human samples and as directed by the Institutional
Review Board of The University of Texas Medical School
at Houston.
Transgenic mice
APPSwe/PSEN1ΔE9 transgenic mice were obtained from
Jackson Laboratory (Bar Harbor, ME, USA). These mice
over-express the human version of amyloid precursor
protein (APP) harboring the Swedish double mutation
(K670M and N671L) and the human presenilin-1 proteinwith the DeltaE9 mutation (PSEN1-ΔE9) [33]. Treated an-
imals were housed in groups of up to 5 in individually
ventilated cages under standard conditions (22°C, 12 h
light–dark cycle) receiving food and water ad libitum. All
animal manipulation was in agreement with NIH guide-
lines and approved by the Animal Welfare Committee of
the University of Texas – Medical School at Houston. 5–8
animals per experimental group were used as indicated in
each section. Males and females were indistinctly used
(overall 43% males, 57% females).
Preparation and characterization of human brain inocula
Frozen cingulate cortex sections of AD, MCI, NDAN
and aged non-demented individuals were homogenized
at 10% (w/v) in ice-cold PBS containing a cocktail of pro-
tease inhibitors (Roche Diagnostics GmbH, Mannheim,
Germany). Resulting homogenates were stored at −80°C
until used for animal injection. In order to measure the
amount of insoluble Aβ in each case, 200 μL aliquots of
each sample were centrifuged at 100,000×g for 1 h and
4°C using a L100K Beckman-Coulter ultracentrifuge
(Beckman-Coulter, Brea, CA, USA). Supernatants were re-
covered and saved as “PBS fractions” and pellets were re-
suspended in 200 μL of a 2% SDS solution by pipetting
and sonication. Samples were centrifuged as explained
above and the supernatants were diluted 40 times in EC
buffer (0.02 M phosphate buffer, pH 7, 0.4 M NaCl, 2 mM
bovine serum albumin, 0.05% CHAPS and 0.05% sodium
azide). Pellets were resuspended in 200 μL of 70% formic
acid (FA) and centrifuged for 30 minutes using the
same temperature and speed previously described. Result-
ing supernatants ("FA fractions") were diluted 20 times in
1 M Tris buffer (pH 11) to adjust pH. All resulting sam-
ples were stored at −80°C until measured by an ELISA kit
able to specifically detect Aβ40 and Aβ42 (Invitrogen,
Carlsbad, CA, USA). Histological characterization was
performed as described below.
Intra-cerebral inoculation of brain extracts
~30 days-old APPSwe/PSEN1ΔE9 mice were intra-cere-
brally injected with 10 μL of 10% (w/v) human cingulate
cortex homogenate. Briefly, mice were anesthetized
using isofluorane. Skin was incised and a small hole was
drilled in the skull. Samples (brain homogenates and
PBS) were injected into the right hippocampus using the
following coordinates as measured from bregma: antero-
posterior (AP), -1.8 mm; medio-lateral (ML), -1.8 mm;
dorso-ventral (DV), -1.8 mm. When finishing treatment,
skin was closed using surgical suture. Animals were placed
on a thermal pad until recovery and monitored daily for
several days. Mice were sacrificed by CO2 inhalation
at ~150 days after treatment. Brains were removed
and the right (injected) hemisphere was stored in 10%











Figure 1 (See legend on next page.)
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Figure 1 Aβ deposition patterns in the brain of AD, MCI, NDAN, and Aged control individuals. (a) The Aβ aggregation profile in the
cingulate cortex of a typical AD case was compared to the one present in MCI and NDAN individuals. Slides were stained with an anti-Aβ (4G8)
antibody, thioflavin S (ThS) and anti-hyperphosphorylated tau protein (AT8) antibody. Brain slices from an aged non-demented control did not
show any AD-associated characteristic (right panels). The scale bar corresponds to 100 μm. (b and c) Aβ levels in these brains were evaluated by
serial extraction and ELISA as described in Methods. The quantity of Aβ40 (b) and Aβ42 (c) was measured using ELISA kits specifically designed to
identify these peptides. PBS, Phosphate Buffer Saline; SDS, Sodium Dodecyl Sulfate; FA, Formic Acid. The values were expressed as means ± SEM
of the different brains used. Samples were measured in duplicates.
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10-μm-thick serial slices from all animal groups (n = 5-8/
group; 5 sections/stain/animal) were processed in parallel
for histological analyses. For immunohistochemistry, sec-
tions were deparaffinazed and the endogenous peroxidase
activity was blocked with 3% H2O2/10% methanol in
PBS for 20 min. Then, brain sections were incubated in
formic acid 85% for 5 min for antigen retrieval. The
sections were incubated overnight at room temperature
with the mouse anti-Aβ antibody at a 1:1000 dilutiona
b
c












Figure 2 Time-course of Aβ aggregation in brains of APPSwe/PS1ΔE9 m
analyzed by histological staining with an anti-Aβ (4G8) antibody. Represent
(a) and hippocampal areas (b). The burden of amyloid deposits was measu
means ± SEM of the different animals used in each group. The scale bar co(Covance, Princeton, NJ). After washing, sections were in-
cubated for 1 h with an HRP-linked secondary sheep anti-
mouse antibody at a 1:1000 dilution (GE Healthcare, Little
Chalfont, UK). Peroxidase reaction was visualized using
DAB Kit (Vector) following the manufacturer’s instruc-
tions. Finally, sections were dehydrated in graded ethanol,
cleared in xylene, and cover-slipped with DPX mounting
medium (Innogenex, San Ramon, CA). A similar approach
was used for the detection of hyper-phosphorylated tau in
human samples (AT8 antibody, 1:100 dilution; Pierce,d
7 months 8 months 
ice. Brains from 5, 6, 7, and 8 months old animals (n = 5-8) were
ative pictures of Aβ deposition in these mice are shown for the cortical
red in cortex (c) and hippocampus (d). The values were expressed as






Figure 3 (See legend on next page.)
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Figure 3 Injection of brain extracts from MCI and NDAN individuals induce Aβ aggregation in the cortex of AD-transgenic mice.
Serial brain slices of animals inoculated with brain homogenates from different sources (n = 5-8) were analyzed by histological staining using an
anti-Aβ (4G8) antibody. (a) Representative pictures of the Aβ deposits in different experimental groups and untreated 6 month old animals in
cortical area are shown. (b) Magnification of the regions labeled in rectangles in panel (a) of AD-, MCI-, and NDAN-inoculated animals are shown.
The scale bar corresponds to 250 μm in (a) and 100 μm in (b). The burden of amyloid deposits was compared among all different control and
experimental groups. The 4G8-immunoreative area was measured and divided by the total brain area analyzed (Aβ burden) in the cortex (c) of
each group.
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bated in ThS (Sigma) solution (0.025% in 50% ethanol) for
5–10 min after deparaffinization. Sections were dehy-
drated in graded ethanol, cleared in xylene, and cover-
slipped with DPX mounting medium (Innogenex, San
Ramon, CA).
Quantification of amyloid load by image analysis
Briefly, sagittal slices of all animal groups (n = 5-8 per
group) were examined under a microscope (DMI6000B,
Leica, Buffalo Grove, IL, USA) and image analyses quan-
tification was performed using the ImagePro software
(Rockville, MD, USA). 4G8 immunohistochemistry and
ThS staining were quantified in every tenth sections, in
a total of 5 sections. All 4G8 and ThS reactive plaques
(parenchymal and vascular, induced and naturally occur-
ring) were included in the analyses. Burden was defined
as the area of the brain labeled per total area analyzed
(data analyses in cortex included all cortical areas). Bur-
den quantification was performed by an investigator
blinded to the experimental groups.
Statistical analysis
Data were expressed as means ± standard error (SEM).
Skewness/kurtosis statistic test was used to confirming
normal distribution of the data. In all the groups, one-
way analysis of variance (ANOVA) followed by a Tukey's
multiple comparison analysis was used to determine
differences among the groups. The values are expressed
as means ± SEM. Data was analyzed using the Graph
Pad prism software, version 5.0. *p < 0.05, **p < 0.01,
***p < 0.001. Statistical differences were considered signifi-
cant for values of p < 0.05.
Results
Aβ pathology in AD, MCI and NDAN donor brains
The aggregation and deposition of proteins is one of the
main pathological features of AD [3]. To compare the
neuropathological changes in MCI and NDAN with the
ones observed in a classical AD case, we characterized
brain samples from individuals affected by these condi-
tions using different histological techniques. Formalin-
fixed samples from the cingulate cortex were stained
with thioflavin-S (ThS) to identify amyloid structures,
and immunostained using the 4G8 and AT8 antibodiesto detect Aβ deposits and hyperphosphorylated-tau, re-
spectively (Figure 1). Extensive accumulation of ThS re-
active Aβ deposits was found in the brain of MCI and
NDAN individuals (Figure 1a, upper and middle panels),
comparable to the one found in the brain from a con-
firmed AD case. For all three cases, a wide variety of Aβ
arrangements, such as parenchymal mature plaques, dif-
fuse aggregates, vascular deposits, and intracellular struc-
tures were found. However, established tau pathology was
identified only in the AD brain (Figure 1a, lower panels);
MCI brains did not display AT8-positive neurons and
NDAN samples showed only a couple of reactive neurons
in several slices analyzed. As expected, all these patho-
logical characteristics were absent in the brain of a non-
demented individual (Figure 1a, right panels).
To further characterize these specimens, we quantified
the amount of soluble/insoluble Aβ after serial extrac-
tion in phosphate buffered saline (PBS), sodium dodecyl
sulfate (SDS), and formic acid (FA) coupled to human-Aβ
ELISA. Whereas the levels of insoluble Aβ40 (SDS and FA
fractions) in the MCI brain were higher compared to the
other samples (Figure 1b), the concentration of this mol-
ecule in the NDAN preparation showed similar levels to
the one observed in a non-demented aged individual, used
as control. Interestingly, the concentration of insoluble
Aβ42 was similar among the AD, MCI and NDAN cases
(Figure 1c). Only the brain sample obtained from the aged
control showed lower levels of this peptide. The amount
of SDS-insoluble/formic acid-soluble Aβ42 (representing
the most aggregated Aβ species) in AD, MCI and
NDAN was ~60-fold higher than in the aged control
brain (Figure 1c).
Characterization of APPSwe/PSEN1ΔE9 mice for studies of
induction of Aβ amyloidosis
Several AD-mouse models have been used to study the
transmissibility of Aβ misfolding. Most of the transgenic
lines previously used involve overexpression of either
the wild type or mutant form of the human amyloid
precursor protein (APP). Before starting our study, we
investigated the appropriate time-frame to assess an
exogenous Aβ seeding effect in the double transgenic
mouse model used in this study. For this purpose, we
followed the time-course of Aβ aggregation and depos-
ition in the brain of APPSwe/PSEN1ΔE9 mice (at 5, 6, 7
a Untreated PBS Aged 
AD MCI NDAN 
b AD MCI NDAN 
c
Figure 4 (See legend on next page.)
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Figure 4 APPSwe/PSEN1ΔE9 mice inoculated with AD and MCI extracts display higher Aβ deposition in the hippocampus. (a)
Representative pictures of the deposits stained with the 4G8 antibody in the hippocampus of experimental and control animals (n = 5-8). (b)
Magnification of the labeled regions (corpus callosum) in the pictures shown in (a). The scale bar corresponds to 250 μm in (a) and 100 μm in
(b). Image analysis was done to quantify the burden of amyloid deposits in the hippocampal area in each group (c). The Aβ deposition was
compared among all control and experimental groups.
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Previous reports suggest that these transgenic animals
first start exhibiting amyloid deposits at 4–5 months of
age and have extensive plaque deposition at 12 months
old [34]. We confirmed these results by observing a time
dependent increase of Aβ deposition in both cortex
(Figure 2a and 2c) and hippocampus (Figure 2b and 2d).
Our data clearly shows that the inflection point in terms
of amyloid deposition for this transgenic line is between
6 and 7 months old. The Aβ burden at 7 months old
was ~5-fold (cortex) and ~4-fold (hippocampus) higher
than in 6 months old mice. Brain samples from male
and female subjects showed comparable amounts of Aβ
deposits within the same group.
Injection of brain extracts from MCI and NDAN
individuals induces Aβ aggregation in APPSwe/PSEN1ΔE9
mice
To test the hypothesis that the sole presence of Aβ
aggregates, regardless of the clinical signs, is required
to accelerate Aβ deposition in AD-mice, brain ex-
tracts from patients affected by MCI or NDAN were
intra-cerebrally (i.c.) injected into APPSwe/PSEN1ΔE9
mice at ~1 month old. Additionally, untreated APPSwe/
PSEN1ΔE9 mice, as well as mice injected with PBS or brain
homogenates obtained from either an AD patient or an
aged non-demented individual, were used as controls.
All animals were sacrificed ~5 months after inoculation
(6 months old), and brains were collected for histopatho-
logical analyses. Since seeding effects strongly depends on
the incubation periods, the time point selected to analyze
the animals was chosen to provide sufficient time to ob-
serve an effect and avoid a possible masking due to the
endogenous appearance of brain amyloidosis. Brain slices
were stained with antibodies against Aβ and the burden of
this peptide was measured in hippocampus (injection site).
In order to assess if seeding expands from its original
placement, we also checked brain cortex, which is an area
strongly affected by Aβ lesions in AD patients. As ex-
pected, we observed a higher amount of amyloid load in
mice injected with the AD extract compared to 6 month
old untreated animals and mice injected with PBS or an
aged-control brain (Figures 3c and 4c). Strikingly, we
found that animals inoculated with the MCI extract
had a substantially higher amount of Aβ deposits
compared to the control groups (Figures 3 and 4). The Aβ
burden was ~5-fold (cortex, Figure 3c) and ~11-fold(hippocampus, Figure 4c) higher compared to that ob-
served in 6 months-old untreated animals. The amyloid
load in the cortex of these animals was similar to the one
observed in mice inoculated with AD brain (Figure 3c),
but the amount in hippocampus was higher (Figure 4c).
Interestingly, brains from animals inoculated with the
NDAN extract also showed an increased deposition of
amyloid aggregates, displaying a high amount of Aβ pla-
ques in the cortical area (Figure 3c) in a similar way as ob-
served for the animals injected with the AD and MCI
inocula. The induction of Aβ aggregation by NDAN in the
cortex was ~4-fold higher than in 6 months old untreated
animals (Figure 3c); however, this treatment did not show
any statistically significant difference in the hippocampal
area (Figure 4). These results demonstrate that MCI and
NDAN brain extracts can accelerate Aβ pathology in a
similar manner as AD samples. Nevertheless, the presence
of extensive-diffuse accumulation of Aβ reactive deposits
in the corpus callosum (Figure 4a) was different from
the typical aggregates naturally generated in this model
(Figure 2a and 2b).
To specifically evaluate the formation of fibrillar amy-
loid deposits, ThS staining was performed in brains of
animals from all experimental and control groups
(Figure 5). ThS-reactive deposits were observed mostly in
the corpus callosum and fimbria of animals injected with
AD or MCI brain extracts (Figure 5a and 5b). Interest-
ingly, the extent of ThS burden in AD and MCI injected
animals was lower compared to the Aβ burden measured
by antibody binding (Figures 3 and 4), and only reached a
statistical significant increase in the hippocampus of ani-
mals inoculated with the MCI extract (Figure 5c).
Discussion
A series of recent and exciting studies have opened the
possibility that the pathological accumulation of mis-
folded protein aggregates implicated in AD and other
disorders of protein misfolding could be inducible in
a similar manner as prions propagate prion diseases
[26-30]. At this time, it is unknown whether the process
of transmission of protein misfolding operates only in
the spreading of the pathological alterations among
cells within an affected individual or can also occur,
under certain conditions, to transmit the pathology from
individual-to-individual, as described for Creutzfeldt-
Jakob disease (CJD). From the experiments performed in







Figure 5 (See legend on next page.)
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Figure 5 Injections of brain extracts from AD and MCI patients increase fibrillar Aβ deposition in AD-transgenic animals. Hippocampal
tissue from brain treated and untreated animals (n = 5-8) were stained with ThS and analysed with an epifluorescent microscope. The burden of
ThS-positive deposits was compared among all different control and experimental groups. Representative pictures of the deposits in the hippocampus of all
groups are shown (a). The scale bar corresponds to 250 μm. (b) Magnification of the regions (corpus callosum in AD and MCI, dentate gyrus in NDAN) labeled
in rectangles in panel (a). Scale bar correspond to 100 μm. (c) The ThS stained area was measured and divided by the total brain area analyzed (ThS burden).
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mogenates containing aggregates. However, future ex-
periments should address whether the pathology can be
induced by more practical and relevant routes of expo-
sure to materials not coming from terminally-sick indi-
viduals. In this sense, a putative transmissible origin of
Aβ pathology would seem more plausible if Aβ depo-
sition can be also induced by exposure to materials de-
rived from “pre-symptomatic” or “a-symptomatic” cases
of AD, since these individuals are more prone to act as
donors for tissues and fluids designated for human use.
In order to address this issue, we analyzed the amyloid
induction capability of samples from individuals affected
by MCI (considered as a pre-symptomatic version of AD)
and NDAN (which would correspond to an a-sympto-
matic form of the disease). The particular samples used in
this study showed similar amounts of insoluble Aβ in the
cingulate cortex and abundant accumulation of amyloid
plaques, mostly in cortical and hippocampal areas of the
brain. By intra-cerebrally challenging APPSwe/PSEN1ΔE9
transgenic mice with these samples, we demonstrated that
the sole presence of Aβ aggregates, regardless of the pre-
sence of clinical signs, was sufficient to induce Aβ depo-
sition. Although previous reports have shown a limited
induction of Aβ aggregation when brain samples from
non-demented individuals were injected to tg2576 [22]
and APP23 [23] mice, no reports have shown before a
comparison with the pathological induction produced by
an AD brain. Since MCI and NDAN samples did not ex-
hibit some of the other alterations typical of AD (e.g.
neurofibrillary tangles), our results indirectly support the
concept that Aβ aggregates are likely the culprit for the
pathological induction. The later conclusion has been
strongly supported by the elegant immuno-depletion
experiments performed by Jucker and colleagues [23]
and the induction of pathology by synthetic Aβ aggre-
gates [35].
Importantly, the seeding effect of AD, MCI and NDAN
samples was observed in the cerebral cortex, a brain re-
gion anatomically separated from the one used for injec-
tion. These results confirm recent findings from us and
others showing that Aβ aggregates appear also in the cor-
tex after intrahippocampal injection, suggesting that the
pathology can spread to areas other than the injection site
[22-24]. This is important, since tissue spreading is
one of the main functional features of prion-like proteins
[30]. Our results indicate that amyloid seeds coming fromMCI and NDAN individuals induced the formation of
Aβ deposits with features slightly different than those
observed spontaneously in the brain of older untrea-
ted transgenic mice. Induced lesions showed a higher
proportion of aggregates in the corpus callosum area
and structures with lower degree of staining with ThS
than those naturally occurring in these animals at ad-
vanced age. Importantly, brain homogenate from an
aged individual lacking of detectable Aβ structures by
histological analyses failed to induce plaque deposi-
tion in these mice.Conclusions
Our findings demonstrate the prion-like behavior of Aβ
aggregates coming from people not formally considered
as affected by AD. Hundreds of cases of human-to-
human prion transmission have been reported involving
blood transfusions, hormone transfer from cadaveric
preparations, tissue transplants, and use of contaminated
surgical instruments [36]. Importantly, in all these cases,
the transmission was from people at the pre-sympto-
matic stage of the prion disease. Due to their lack of
clinical symptoms, MCI and NDAN affected individuals
are currently not considered sick, and as in pre-symp-
tomatic CJD transmission, they might be the ones with
the higher potential to transmit misfolded seeds to
healthy population. Although a recent epidemiological
study showed that individuals receiving human-derived
growth hormone from future or current AD patients
were not at higher risk of developing dementia [37], add-
itional studies directed to confirm/discard the possibility
of inter-individual transmission of amyloid pathology in
humans are necessary.Competing interests
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